Biopsies from up to 14% of patients with non-small-cell lung cancer (NSCLC) showing resistance to epidermal growth factor receptor (EGFR) tyrosine kinase therapy ascertain histologic transformation (HT) to SCLC, which is estimated to kill around 250,000 patients globally, every year. In a study published in Science on Feb. 9, 2024, researchers from Weill Cornell Medicine have dissected that complex process using a genetically engineered mouse model of pulmonary HT. Read More
The rare hereditary fibrinogen disorder hypodysfibrinogenemia is characterized by fibrinogen defects, which can cause thrombotic and hemorrhagic phenotypes that are not always predicted by routine coagulation tests. Researchers from Academic Hospital Maastricht aimed to characterize the genetic profile of a family with hypodysfibrinogenemia and predict bleeding and/or thrombotic phenotypes in asymptomatic family members using innovative testing. Read More
Researchers from the University of Queensland and affiliated organizations recently presented preclinical data for the novel C3a receptor (C3aR) antagonist JR-14a, being developed as a neuroprotective agent for the treatment of post-stroke neuroinflammation. Read More
Alys Pharmaceuticals Inc. has launched with a focus in the field of immuno-dermatology. Supported by $100 million in financing from Medicxi, Alys was formed through the aggregation of six asset-centric Medicxi companies: Aldena Therapeutics Inc., Graegis Pharmaceuticals Ltd., Granular Therapeutics Ltd., Klirna Biotech Sàrl, Nira Biosciences Inc. and Vimela Therapeutics Inc. Read More
Early steps in cancer development are closely linked to fibroblast senescence and their transformation into tumor-promoting cancer-associated fibroblasts (CAFs). Read More
Elicera Therapeutics AB has received approval from the Swedish Medical Products Agency to start a phase I/II study of chimeric antibody receptor (CAR) T-cell therapy ELC-301 in patients with refractory or relapsed B-cell lymphoma. Read More
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is characterized by accumulation of triglycerides (TGs) in liver hepatocytes, and which can progress into chronic liver disease or even hepatocellular carcinoma. Read More
Aurigene Oncology Ltd. has divulged cyclin-dependent kinase 12 (CDK12) and/or cyclin-dependent kinase 13 (CDK13) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, infections, amyotrophic lateral sclerosis, frontotemporal dementia, spinal and bulbar muscular atrophy, spinocerebellar ataxia and Huntington’s disease, among others. Read More
The most common genetic cause of hereditary deafness in humans are mutations in the GJB2 gene, especially the 35delG and 235delC mutations. At the recent ARO meeting, researchers from Ear Nose and Throat Hospital of Fudan University presented the creation of a novel mouse model for studying the pathogenic mechanisms of hereditary deafness resulting from these mutations. Read More
Les Laboratories Servier SAS and Vernalis (R&D) Ltd. have described induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors acting as apoptosis inducers reported to be useful for the treatment of cancer and autoimmune diseases. Read More
Bleeding of unknown cause is a group of rare disorders that are still difficult to accurately diagnose. A case report on a patient with hematoma in the perineal region after her first delivery was presented. Read More
Nonhuman primate (NHP) models may contribute to advance research in Alzheimer’s disease (AD) thanks to their genetic, anatomical and physiological similarities with humans. However, their use in AD research is limited by significant challenges, including long generation times, ethical considerations and technical challenges of genetic modification. Read More
